A weekly 4‐methylpyrazole treatment attenuates the development of non‐obese metabolic dysfunction‐associated steatotic liver disease (MASLD) in male mice: Role of JNK. Here, MAPK8 is linked to metabolic dysfunction-associated steatotic liver disease.